This listing of claims will replace all prior versions, and listings, of claims in the application.

Listing of Claims:

1. (Original) A compound of formulae I or II having the structure



I



II

wherein

R_1 is hydrogen, alkyl of 1-6 carbon atoms, alkenyl of 2-7 carbon atoms, cycloalkyi of 3-8 carbon atoms, cycloalkenyl of 4-8 carbon atoms, aryl of 6-20 carbon atoms, arylalkyl of 7-26 carbon atoms, or a saturated, unsaturated, or partially unsaturated heterocyclic ring or ring system of 4-14 atoms, containing 1-4 heteroatoms selected from N, O, and S;

R_2, R_3, R_4, and R_5, are each, independently, hydrogen, alkyl of 1-6 carbon atoms, alkenyl of 2-7 carbon atoms, hydroxy, alkoxy of 1-6 carbon atoms, aryloxy of 6-20 carbon atoms, halogen, trifluoromethyl, -CN, $-NO_2$, -CHO, or $-CO_2R_{11}$;

R_6, R_7, R_8, and R_9, are each, independently, hydrogen, alkyl of 1-6 carbon atoms, alkenyl of 2-7 carbon atoms, hydroxy, alkoxy of 1-6 carbon atoms, aryloxy of 6-20 carbon atoms, halogen, trifluoromethyl, $-CO_2 R_{11}$, aryl of 6-20 carbon atoms, arylalkyl of 7-26 carbon atoms, or a saturated, unsaturated, or partially unsaturated heterocyclic ring

or ring system of 4-14 atoms, containing 1-4 heteroatoms selected from N, O, and S wherein the nitrogen or sulfur atoms are optionally oxidized and nitrogen is optionally quaternized;

R_{10} is hydrogen, -CO R_{11},-CONH R_{11}, -P(=O)(OH)OR_{11}, or -$CO(CH_2)_nCH(NHR_{12})CO_2R_{11}$;

R_{11} is hydrogen, alkyl of 1-6 carbon atoms, aryl of 6-20 carbon atoms, or arylalkyl of 7-26 carbon atoms; R_{12} is hydrogen or-CO_2R_{11};

n = 0-3,

or a pharmaceutically acceptable salt thereof.

2. (Original) The compound according to claim 1, wherein

R_1 is alkyl of 1-6 carbon atoms, alkenyl of 2-7 carbon atoms, cycloalkyl of 3-8 carbon atoms, cycloalkenyl of 4-8 carbon atoms, or a saturated, unsaturated, or partially unsaturated heterocyclic ring or ring system of 4-14 atoms, containing 1-4 heteroatoms selected from N, O, and S;

R_2 is hydrogen, alkyl of 1-6 carbon atoms, alkenyl of 2-7 carbon atoms, hydroxy, alkoxy of 1-6 carbon atoms, or halogen;

R_7 and R_9, are each, independently, hydrogen, alkyl of 1-6 carbon atoms, hydroxy, halogen, trifluoromethyl, -CO_2R_{11}, aryl of 6-20 carbon atoms, arylalkyl of 7-26 carbon atoms, or a saturated, unsaturated, or partially unsaturated heterocyclic ring or ring system of 4-14 atoms, containing 1-4 heteroatoms selected from N, O, and S;

or a pharmaceutical acceptable salt thereof.

3. (Original) The compound according to claim 2, wherein

R_1 is alkyl of 1-6 carbon atoms, alkenyl of 2-7 carbon atoms, cycloalkyl of 3-8 carbon atoms, or cycloalkenyl of 4-8 carbon atoms;

R_2 is hydrogen, alkyl of 1-6 carbon atoms, halogen, or hydroxy;

R_9 is alkyl of 1-6 carbon atoms, halogen, trifluoromethyl, -CO_2R_{11}, aryl of 6-20 carbon atoms, arylalkyl of 7-26 carbon atoms, or a saturated, unsaturated, or partially unsaturated heterocyclic ring or ring system of 4-14 atoms, containing 1-4 heteroatoms selected from N, 0, and S;

R_{10} is hydrogen;

or a pharmaceutically acceptable salt thereof.

4. (Original) The compound according to claim 3, wherein

R_1 is alkyl of 1-6 carbon atoms or alkenyl of 2-7 carbon atoms;

R_9 is alkyl of 1-6 carbon atoms, halogen, or trifluoromethyl; or a pharmaceutically acceptable salt thereof.

5. (Original) The compound according to claim 1, which is

a) 4-(6-chloro-5-fluoro-1-methyl-1H-indazol-3-yl)phenol;

b) 4-(7-chloro-1 -methyl-1 H-indazol-3-yl)phenol;

c) 4-(1H-indazol-3-yl)phenol;

d) 4-(6-chloro-5-fluoro-1 H-indazol-3-yl)phenol;

e) 4-(6-chloro-1 H-indazol-3-yl)phenol;

f) 4-(1-butyl-1 H-indazol-3-yl)phenol;

g) 4-(1 -benzyl-7-chloro-1 H-indazol-3-yl)phenol;

h) 4-[1 -benzyl-7-(trifluoromethyl)-1 H-indazol-3-yl]benzene-1,3-diol;

i) 4-(1 -benzyl-7-fluoro-1 H-indazol-3-yl)phenol;

j) 4-[1 -benzyl-7-(trifluoromethyl)-1 H-indazol-3-yl]phenol;

k) 4-(1 -benzyl-7-chloro-1 H-indazol-3-yl)benzene-1,3-diol;

l) 4-(1 -benzyl-7-fluoro-1 H-indazol-3-yl)-1,3-benzenediol;

m) 4-[1 -(2-hydroxyethyl)-1 H-indazol-3-yl]phenol;

n) 4-[1 -(2-hydroxyethyl)-7-(trifluoromethyl)-1 H-indazol-3-yl]phenol;

o) 4-[1 -methyl-7-(trifluoromethyl)-1 H-indazol-3-yl]benzene-1,3-diol;

p) 4-(5-fluoro-1-methyl-1 H-indazol-3-yl)phenol;

q) 4-[1 -methyl-7-(trifluoromethyl)-1 H-indazol-3-yl]phenol;

r) 4-(7-chloro-1 -methyl-1 H-indazol-3-yl)benzene-1,3-diol;

s) 4-[1 -methyl-5-(trifluoromethyl)-1 H-indazol-3-yl]phenol;

t) 4-(5-fluoro-1 -methyl-1 H-indazol-3-yl)benzene-1,3-diol;

u) 4-[1 -methyl-7-(trifluoromethyl)-1 H-indazol-3-yl]benzene-1,2-diol;

v) 4-(1 -butyl-7-chloro-1 H-indazol-3-yl)phenol;

w) 4-[1 -benzyl-5-(trifluoromethyl)-1 H-indazol-3-yl]benzene-1,3-diol;

x) 4-(1-benzyl-1H-indazol-3-yl)benzene-1,3-diol;

y) 4-[7-fluoro-1 -(2-hydroxyethyl)-1 H-indazol-3-yl]phenol;

z) 4-[5-fluoro-1 -(2-hydroxyethyl)-1 H-indazol-3-yl]benzene-1,3-diol;

aa) 4-[1 -(2-chlorophenyl)-6-hydroxy-1 H-indazol-3-yl]benzene-1,3-diol;

bb) 4-[6-hydroxy-1 -(4-methoxyphenyl)-1 H-indazol-3-yl]benzene-1,3-diol;

cc) 4-[6-hydroxy-1 -(2-methoxyphenyl)-1 H-indazol-3-yl]benzene-1,3-diol;

dd) 4-{6-hydroxy-1 -[4-(trifluoromethoxy)phenyl]-1 H-indazol-3-yl}benzene- 1,3-diol;

ee) 4-[1 -(3-bromophenyl)-6-hydroxy-1 H-indazol-3-yl]benzene-1,3-diol;

ff) 4-[1 -(4-bromophenyl)-6-hydroxy-1 H-indazol-3-yl]benzene-1,3-diol;

gg) 4-[3-(2,4-dihydroxyphenyl)-6-hydroxy-1 H-indazol-1 -yl]benzonitrile;

hh) 4-[1 -(3-chlorophenyl)-6-hydroxy-1 H-indazol-3-yl]benzene-1,3-diol;

ii) 4-(1 -ethyl-6-hydroxy-1 H-indazol-3-yl)benzene-1,3-diol;

jj) 4-(6-hydroxy-1 -propyl-1 H-indazol-3-yl)benzene-1,3-diol;

kk) 4-(1 -butyl-6-hydroxy-1 H-indazol-3-yl)benzene-1,3-diol;

ll) 4-(1-cyclohexyl-6-hydroxy-1 H-indazol-3-yl)benzene-1,3-diol;

mm) 4-[6-hydroxy-1 -(2,2,2-trifluoroethyl)-1 H-indazol-3-yl]benzene-1,3-diol;

nn) 4-[1 -(3-fluorophenyl)-6-hydroxy-1 H-indazol-3-yl]benzene-1,3-diol;

oo) 4-[6-hydroxy-1 -(4-methylphenyl)-1 H-indazol-3-yl]benzene-1,3-diol;

pp) 4-[1 -(2-fluorophenyl)-6-hydroxy-1 H-indazol-3-yl]benzene-1,3-diol;

qq) 4-[6-hydroxy-1-(3-methylphenyl)-1 H-indazol-3-yl]benzene-1,3-diol;

rr) 4-(7-chloro-1 -cyclohexyl-1 H-indazol-3-yl)phenol;

ss) 4-[1 -(4-bromophenyl)-7-(trifluoromethyl)-1 H-indazol-3-yl]phenol;

tt) 4-[1 -cyclohexyl-7-(trifluoromethyl)-1 H-indazol-3-yl]phenol;

uu) 4-(7-methyl-1 H-indazol-3-yl)phenol;

vv) 4-[1-(3-chloro-4-fluorophenyl)-6-hydroxy-1 H-indazol-3-yl]benzene-1,3-diol;

ww) 4-{6-hydroxy-1 -[3-(trifluoromethyl)phenyl]-1 H-indazol-3-yl}benzene-1,3-diol;

xx) 4-[6-hydroxy-1 -(3-nitrophenyl)-1 H-indazol-3-yl]benzene-1,3-diol;

yy) 4-[6-hydroxy-1 -(4-isopropylphenyl)-1 H-indazol-3-yl]benzene-1,3-diol;

zz) 4-{6-hydroxy-1 -[4-(methylsulfonyl)phenyl]-1 H-indazol-3-yl}benzene-1,3-diol;

aaa) 4-(7-methyl-1 -propyl-1 H-indazol-3-yl)phenol;

bbb) 4-(1-isopropyl-7-methyl-1H-indazol-3-yl)phenol;

ccc) 4-(7-chloro-1 -pentyl-1 H-indazol-3-yl)phenol;

ddd) 4-(7-chloro-1 -propyl-1 H-indazol-3-yl)phenol;

eee) 4-(7-chloro-1 -isopropyl-1 H-indazol-3-yl)phenol;

fff) 4-[1 -pentyl-7-(trifluoromethyl)-1 H-indazol-3-yl]phenol;

ggg) 4-[1-isopropyl-7-(trifluoromethyl)-1 H-indazol-3-yl]phenol;

hhh) 4-[1 -propyl-7-(trifluoromethyl)-1 H-indazol-3-yl]phenol;

iii) 4-(7-methyl-2-propyl-2H-indazol-3-yl)phenol;

jjj) 4-[2-isopropyl-7-methyl-2H-indazol-3-yl]phenol;

kkk) 4-(7-chloro-2-pentyl-2H-indazol-3-yl)phenol;

lll) 4-(7-chloro-2-propyl-2H-indazol-3-yl)phenol;

mmm) 4-(7-chloro-2-isopropyl-2H-indazol-3-yl)phenol;

nnn) 4-[1 -butyl-6-(trifluoromethyl)-1 H-indazol-3-yl]phenol;

ooo) 4-(1 -butyl-6-chloro-1 H-indazol-3-yl)phenol;

ppp) 4-(7-fluoro-1 -methyl-1 H-indazol-3-yl)phenol;

qqq) 4-(1H-indazol-3-yl)benzene-1,2-diol;

rrr) 4-(7-fluoro-1 H-indazol-3-yl)phenol;

sss) 4-[1 -butyl-5-(trifluoromethyl)-1 H-indazol-3-yl]phenol;

ttt) 4-(1 -cyclohexyl-7-fluoro-1 H-indazol-3-yl)phenol;

uuu) 4-(1 -allyl-7-fluoro-1 H-indazol-3-yl)phenol;

vvv) 4-(1-allyl-7-methyl-1H-indazol-3-yl)phenol;

www) 4-[1 -allyl-7-(trifluoromethyl)-1 H-indazol-3-yl]phenol;

xxx) 4-(7-chloro-1 -cyclopentyl-1 H-indazol-3-yl)phenol;

yyy) 4-(7-fluoro-1 -propyl-1 H-indazol-3-yl)phenol;

zzz) 4-(7-fluoro-1 -isopropyl-1 H-indazol-3-yl)phenol;

aaaa) 4-(1-cyclopentyl-7-fluoro-1H-indazol-3-yl)phenol;

bbbb) 4-[1 -butyl-7-(trifluoromethyl)-1 H-indazol-3-yl]phenol;

cccc) 4-(1 -butyl-7-fluoro-1 H-indazol-3-yl)phenol;

dddd) 4-[2-allyl-7-(trifluoromethyl)-2H-indazol-3-yl]phenol;

eeee) 4-(7-chloro-2-cyclopentyl-2H-indazol-3-yl)phenol;

ffff) 4-(2-cyclopentyl-7-fluoro-2H-indazol-3-yl)phenol;

gggg) 4-(7-fluoro-2-isopropyl-2H-indazol-3-yl)phenol;

hhhh) 4-(7-fluoro-2-propyl-2H-indazol-3-yl)phenol;

iiii) 4-[7-fluoro-1-(3,3,3-trifluoropropyl)-1 H-indazol-3-yl)phenol;

jjjj) 4-[1-allyl-7-(trifluoromethyl)-1H-indazol-3-yl]-3-methylphenol;

kkkk) 3-methyl-4-[1-propyl-7-(trifluoromethyl)-1H-indazol-3-yl]phenol;

llll) 4-[1-allyl-7-(trifluoromethyl)-1H-indazol-3-yl]benzene-1,3-diol;

mmmm) 4-[1-pentyl-7-(trifluoromethyl)-1H-indazol-3-yl]benzene-1,3-diol;

nnnn) 4-[2-allyl-7-(trifluoromethyl)-2H-indazol-3-yl]-3-methylphenol;

oooo) 4-[2-allyl-7-(trifluoromethyl)-2H-indazol-3-yl]-1,3-benzenediol;

pppp) 4-(7-chloro-1 -isopropyl-1 H-indazol-3-yl)-3-methylphenol;

qqqq) 4-(7-chloro-2-isopropyl-2H-indazol-3-yl)-3-methylphenol;

rrrr) 4-(7-chloro-1 -propyl-1 H-indazol-3-yl)-3-methylphenol;

ssss) 4-(7-chloro-2-propyl-2H-indazol-3-yl)-3-methylphenol;

tttt) 4-(1-allyl-7-chloro-1 H-indazol-3-yl)-3-methylphenol;

uuuu) 4-(2-allyl-7-chloro-2H-indazol-3-yl)-3-methylphenol;

vvvv) 4-(1-cyclopentyl-7-fluoro-1 H-indazol-3-yl)-2-methylphenol;

wwww) 4-(7-chloro-1 -cyclopentyl-1 H-indazol-3-yl)-3-methylphenol;

xxxx) 4-(7-chloro-1-isopropyl-1 H-indazol-3-yl)benzene-1,3-diol;

yyyy) 4-(1-allyl-7-chloro-1 H-indazol-3-yl)benzene-1,3-diol;

zzzz) 4-[1-isopropyl-7-(trifluoromethyl)-1H-indazol-3-yl]-3-methylphenol;

aaaaa) 4-(1 -isopropyl-7-thien-3-yl-1 H-indazol-3-yl)phenol;

bbbbb) 4-(1 -isopropyl-7-thien-2-yl-1 H-indazol-3-yl)phenol;

ccccc) 4-{1-isopropyl-7-[4-(methylthio)phenyl]-1H-indazol-3-yl}phenol;

ddddd) 4-{7-[4-(hydroxymethyl)phenyl]-1-isopropyl-1 H-indazol-3-yl}phenol;

eeeee) 4-[3-(4-hydroxyphenyl)-1 -isopropyl-1 H-indazol-7-yl]benzene-1,2-diol;

fffff) 4-[7-(4-ethylphenyl)-1 -isopropyl-1 H-indazol-3-yl]phenol;

ggggg) 4-[7-(1,1'-biphenyl-4-yl)-1 -isopropyl-1 H-indazol-3-yl]phenol;

hhhhh) 4-[7-(2-chlorophenyl)-1 -isopropyl-1 H-indazol-3-yl]phenol;

iiiii) 4-[1 -isopropyl-7-(2-methylphenyl)-1 H-indazol-3-yl]phenol;

jjjjj) 4-(1 -isopropyl-7-phenyl-1 H-indazol-3-yl)phenol;

kkkkk) 4-{1-cyclopentyl-7-[4-(trifluoromethyl)phenyl]-1H-indazol-3-yl}phenol;

lllll) 4-(1 -cyclopentyl-7-thien-2-yl-1 H-indazol-3-yl)phenol;

mmmmm) 4-[1 -cyclopentyl-3-(4-hydroxyphenyl)-1 H-indazol-7-yl]benzene-1,2-diol;

nnnnn) 4-[1 -cyclopentyl-7-(4-ethylphenyl)-1 H-indazol-3-yl]phenol;

ooooo) 4-[7-(2-chlorophenyl)-1 -cyclopentyl-1 H-indazol-3-yl]phenol;

ppppp) 4-[1-cyclopentyl-7-(2-furyl)-1H-indazol-3-yl]phenol;

qqqqq) 4-[1 -cyclopentyl-7-(2-methylphenyl)-1 H-indazol-3-yl]phenol;

rrrrr) 4-(1 -cyclopentyl-7-phenyl-1 H-indazol-3-yl)phenol;

sssss) 4-(1 -isopropyl-7-thien-3-yl-1 H-indazol-3-yl)-3-methylphenol;

ttttt) 4-{7-[(1 E)-hept-1 -enyl]-1 -isopropyl-1 H-indazol-3-yl}-3-methylphenol;

uuuuu) 4-{7-[4-(hydroxymethyl)phenyl]-1-isopropyl-1 H-indazol-3-yl}-3-methylphenol;

vvvvv) 4-[3-(4-hydroxy-2-methylphenyl)-1 -isopropyl-1 H-indazol-7-yl]benzene-1,2-diol;

wwwww) 4-[7-(4-ethylphenyl)-1 -isopropyl-1 H-indazol-3-yl]-3-methylphenol;

xxxxx) 4-[7-(1,1'-biphenyl-4-yl)-1-isopropyl-1 H-indazol-3-yl]-3-methylphenol;

yyyyy) 4-[7-(2-chlorophenyl)-1 -isopropyl-1 H-indazol-3-yl]-3-methylphenol;

zzzzz) 4-[7-(2-furyl)-1 -isopropyl-1 H-indazol-3-yl]-3-methylphenol;

aaaaaa) 4-[1 -isopropyl-7-(2-methylphenyl)-1 H-indazol-3-yl]-3-methylphenol;

bbbbbb) 4-(1 -isopropyl-7-phenyl-1 H-indazol-3-yl)-3-methylphenol;

cccccc) 4-{1-cyclopentyl-7-[4-(methylthio)phenyl]-1 H-indazol-3-yl}-3-methy I phenol;

dddddd) 4-{1 -cyclopentyl-7-[(1 E)-hept-1 -enyl]-1 H-indazol-3-yl}-3-methylphenol;

eeeeee) 4-[1 -cyclopentyl-3-(4-hydroxy-2-methylphenyl)-1 H-indazol-7-yl]benzene-1,2-diol;

ffffff) 4-[1-cyclopentyl-7-(4-ethylphenyl)-1 H-indazol-3-yl]-3-methylphenol;

gggggg) 4-[7-(1,1'-biphenyl-4-yl)-1-cyclopentyl-1 H-indazol-3-yl]-3-methylphenol;

hhhhhh) 4-[7-(2-chlorophenyl)-1 -cyclopentyl-1 H-indazol-3-yl]-3-methylphenol;

iiiiii) 4-[1 -cyclopentyl-7-(2-furyl)-1 H-indazol-3-yl]-3-methylphenol;

jjjjjj) 4-[1-cyclopentyl-7-(2-methylphenyl)-1 H-indazol-3-yl]-3-methylphenol;

kkkkkk) 4-(1 -cyclopentyl-7-phenyl-1 H-indazol-3-yl)-3-methylphenol;

llllll) 4-[7-(1-benzothien-2-yl)-1-cyclopentyl-1 H-indazol-3-yl]-3-methylphenol;

mmmmmm) 4-[7-(2-furyl)-1 -isopropyl-1 H-indazol-3-yl]phenol;

nnnnnn) 4-(7-fluoro-1 -propyl-1 H-indazol-3-yl)-3-methylphenol;

oooooo) 4-(7-fluoro-2-propyl-2H-indazol-3-yl)-3-methylphenol;

pppppp) 4-(7-fluoro-1 -isopropyl-1 H-indazol-3-yl)-3-methylphenol;

qqqqqq) 4-(1-cyclopentyl-7-fluoro-1 H-indazol-3-yl)benzene-1,3-diol;

rrrrrr) 4-(7-fluoro-1-isobutyl-1 H-indazol-3-yl)-3-methylphenol;

ssssss) 4-(7-fluoro-1 -isopropyl-1 H-indazol-3-yl)benzene-1,3-diol;

tttttt) 4-(7-fluoro-2-isopropyl-2H-indazol-3-yl)benzene-1,3-diol;

uuuuuu) 4-(7-fluoro-1 -isobutyl-1 H-indazol-3-yl)benzene-1,3-diol;

vvvvvv) 4-[3-(4-hydroxyphenyl)-1 -propyl-1 H-indazol-7-yl]phenol;

wwwwww) 4-[7-(4-fluorophenyl)-1-propyl-1 H-indazol-3-yl]phenol;

xxxxxx) 4-(7-morpholin-4-yl-1 -propyl-1 H-indazol-3-yl)phenol;

yyyyyy) 4-(7-phenyl-2-propyl-2H-indazol-3-yl)phenol;

zzzzzz) 4-(7-phenyl-1 -propyl-1 H-indazol-3-yl)phenol;

aaaaaaa) 4-(1-cyclopentyl-7-fluoro-1 H-indazol-3-yl)phenyl pivalate;

bbbbbbb) 4-(7-chloro-1-propyl-1 H-indazol-3-yl)phenyl 3,3-dimethylbutanoate;

ccccccc) 4-(7-chloro-1-propyl-1 H-indazol-3-yl)phenyl propionate;

ddddddd) 4-(1-cyclopentyl-7-fluoro-1 H-indazol-3-yl)phenyl acetate;

eeeeeee) 4-(1-cyclopentyl-7-fluoro-1 H-indazol-3-yl)phenyl propionate;

fffffff) 4-(1-cyclopentyl-7-fluoro-1 H-indazol-3-yl)phenyl N-(tert-butoxycarbonyl)glycylglycinate;

ggggggg) 1-tert-butyl 5-[4-(1-cyclopentyl-7-fluoro-1H-indazol-3-yl)phenyl] N-(tert-butoxycarbonyl)-L-glutamate;

hhhhhhh) 4-(1-cyclopentyl-7-fluoro-1 H-indazol-3-yl)phenyl ethylcarbamate;

iiiiiii) 4-(7-chloro-1 -thien-3-yl-1 H-indazol-3-yl)phenol;

jjjjjjj) 4-[1-isopropyl-7-(trifluoromethyl)-1 H-indazol-3-yl]benzene-1,3-diol;

kkkkkkk) methyl 3-(4-hydroxyphenyl)-2-isopropyl-2H-indazole-7-carboxylate;

lllllll) 4-[1 -cyclopentyl-7-(trifluoromethyl)-1 H-indazol-3-yl]benzene-1,3-diol;

mmmmmmm) 4-[1 -(cyclohexylmethyl)-7-(trifluoromethyl)-1 H-indazol-3-yl]benzene-1,3-diol;

nnnnnnn) 4-[1-isobutyl-7-(trifluoromethyl)-1 H-indazol-3-yl]benzene-1,3-diol;

ooooooo) 4-[1 -cyclobutyl-7-(trifluoromethyl)-1 H-indazol-3-yl]benzene-1,3-diol;

ppppppp) 4-[1 -(2-ethylbutyl)-7-(trifluoromethyl)-1 H-indazol-3-yl]benzene-1,3-diol,

or a pharmaceutically acceptable salt thereof.

6. (Original) A pharmaceutical composition, which comprises a compound of formulae I or II having the structure



I



II

wherein

R_1 is hydrogen, alkyl of 1-6 carbon atoms, alkenyl of 2-7 carbon atoms, cycloalkyi of 3-8 carbon atoms, cycloalkenyl of 4-8 carbon atoms, aryl of 6-20 carbon atoms, arylalkyl of 7-26 carbon atoms, or a saturated, unsaturated, or partially unsaturated heterocyclic ring or ring system of 4-14 atoms, containing 1-4 heteroatoms selected from N, O, and S;

R_2, R_3, R_4, and R_5, are each, independently, hydrogen, alkyl of 1-6 carbon atoms, alkenyl of 2-7 carbon atoms, hydroxy, alkoxy of 1-6 carbon atoms, aryloxy of 6-20 carbon atoms, halogen, trifluoromethyl, -CN, $-NO_2$, -CHO, or $-CO_2R_{11}$; R_6, R_7, R_8, and R_9, are each, independently, hydrogen, alkyl of 1-6 carbon atoms, alkenyl of 2-7 carbon atoms, hydroxy, alkoxy of 1-6 carbon atoms, aryloxy of 6-20 carbon atoms, halogen, trifluoromethyl, $-C0_2Rn$, aryl of 6-20 carbon atoms, arylalkyi of 7-26 carbon atoms, or a saturated, unsaturated, or partially unsaturated heterocyclic ring or ring system of 4-

14 atoms, containing 1-4 heteroatoms selected from N, O, and S wherein the nitrogen or sulfur atoms are optionally oxidized and nitrogen is optionally quaternized;

R_{10} is hydrogen, $-COR_{11}$, $-CONHR_{11}$, $-P(=O)(OH)OR_{11}$, or $-CO(CH_2)_nCH(NHR_{12})CO_2R_{11}$;

R_{11} is hydrogen, alkyl of 1-6 carbon atoms, aryl of 6-20 carbon atoms, or arylalkyi of 7-26 carbon atoms; R_{12} is hydrogen or $-CO_2R_{11}$;

n = 0-3,

or apharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.

7. (Original) A method of treating or inhibiting chronic inflammatory disease in a mammal in need thereof, which comprises administering to said mammal an effective amount of a compound of formulae I or II having the structure



I



II

wherein

R_1 is hydrogen, alkyl of 1-6 carbon atoms, alkenyl of 2-7 carbon atoms, cycloalkyi of 3-8 carbon atoms, cycloalkenyl of 4-8 carbon atoms, aryl of 6-20 carbon atoms, arylalkyl of 7-26 carbon atoms, or a saturated, unsaturated, or partially unsaturated heterocyclic ring or ring system of 4-14 atoms, containing 1-4 heteroatoms selected from N, O, and S;

R_2, R_3, R_4, and R_5, are each, independently, hydrogen, alkyl of 1-6 carbon atoms, alkenyl of 2-7 carbon atoms, hydroxy, alkoxy of 1-6 carbon atoms, aryloxy of 6-20 carbon atoms, halogen, trifluoromethyl, -CN, $-NO_2$, -CHO, or $-CO_2R_{11}$;

R_6, R_7, R_8, and R_9, are each, independently, hydrogen, alkyl of 1-6 carbon atoms, alkenyl of 2-7 carbon atoms, hydroxy, alkoxy of 1-6 carbon atoms, aryloxy of 6-20 carbon atoms, halogen, trifluoromethyl, $-CO_2$Rii, aryl of 6-20 carbon atoms, arylalkyl of 7-26 carbon atoms, or a saturated, unsaturated, or partially unsaturated heterocyclic ring or ring system of 4-14 atoms, containing 1-4 heteroatoms selected from N, O, and S wherein the nitrogen or sulfur atoms are optionally oxidized and nitrogen is optionally quaternized;

R_{10} is hydrogen, $-COR_{11}$, $-CONHR_{11}$, $-P(=O)(OH)OR_{11}$ or $-CO(CH_2)_nCH(NHR_{12})CO_2R_{11}$;

R_{11} is hydrogen, alkyl of 1-6 carbon atoms, aryl of 6-20 carbon atoms, or arylalkyl of 7-26 carbon atoms; R_{12} is hydrogen or $-CO_2R_{11}$;

n = 0-3,

or a pharmaceutically acceptable salt thereof.

8. (Original) A method of treating or inhibiting rheumatoid arthritis, spondyloarthropathies, osteoarthritis, psoriatic arthritis, or juvenile arthritis in a mammal in need thereof, which comprises administering to said mammal an effective amount of a compound of formulae I or II having the structure



I



II

wherein

R_1 is hydrogen, alkyl of 1-6 carbon atoms, alkenyl of 2-7 carbon atoms, cycloalkyi of 3-8 carbon atoms, cycloalkenyl of 4-8 carbon atoms, aryl of 6-20 carbon atoms, arylalkyl of 7-26 carbon atoms, or a saturated, unsaturated, or partially unsaturated heterocyclic ring or ring system of 4-14 atoms, containing 1-4 heteroatoms selected from N, O, and S;

R_2, R_3, R_4, and R_5, are each, independently, hydrogen, alkyl of 1-6 carbon atoms, alkenyl of 2-7 carbon atoms, hydroxy, alkoxy of 1-6 carbon atoms, aryloxy of 6-20 carbon atoms, halogen, trifluoromethyl, -CN, $-NO_2$, -CHO, or $-CO_2R_{11}$,

R_6, R_7, R_8, and R_9, are each, independently, hydrogen, alkyl of 1-6 carbon atoms, alkenyl of 2-7 carbon atoms, hydroxy, alkoxy of 1-6 carbon atoms, aryloxy of 6-20 carbon atoms, halogen, trifluoromethyl, $-CO_2Rn$, aryl of 6-20 carbon atoms, arylalkyi of 7-26 carbon atoms, or a saturated, unsaturated, or partially unsaturated heterocyclic ring or ring system of 4-14 atoms, containing 1-4 heteroatoms selected from N, O, and S wherein the nitrogen or sulfur atoms are optionally oxidized and nitrogen is optionally quaternized;

R_{10} is hydrogen, -CO R_{11}, $-CONHR_{11}$, $-P(=O)(OH)OR_{11}$, or $-CO(CH_2)_nCH(NHR_{12})CO_2R_{11}$;

R_{11} is hydrogen, alkyl of 1-6 carbon atoms, aryl of 6-20 carbon atoms, or arylalkyi of 7-26 carbon atoms; R_{12} is hydrogen or $-CO_2R_{11}$;

n = 0-3,

or a pharmaceutically acceptable salt thereof.

9. (Original) A method of treating or inhibiting inflammatory bowel disease, Crohn's disease, ulcerative colitis, or indeterminate colitis in a mammal in need thereof, which

comprises administering to said mammal an effective amount of a compound of formulae I or II having the structure



I



II

wherein

R_1 is hydrogen, alkyl of 1-6 carbon atoms, alkenyl of 2-7 carbon atoms, cycloalkyl of 3-8 carbon atoms, cycloalkenyl of 4-8 carbon atoms, aryl of 6-20 carbon atoms, arylalkyl of 7-26 carbon atoms, or a saturated, unsaturated, or partially unsaturated heterocyclic ring or ring system of 4-14 atoms, containing 1-4 heteroatoms selected from N, O, and S;

R_2, R_3, R_4, and R_5, are each, independently, hydrogen, alkyl of 1-6 carbon atoms, alkenyl of 2-7 carbon atoms, hydroxy, alkoxy of 1-6 carbon atoms, aryloxy of 6-20 carbon atoms, halogen, trifluoromethyl, -CN, $-NO_2$, -CHO, or $-CO_2R_{11}$;

R_6, R_7, R_8, and R_9, are each, independently, hydrogen, alkyl of 1-6 carbon atoms, alkenyl of 2-7 carbon atoms, hydroxy, alkoxy of 1-6 carbon atoms, aryloxy of 6-20 carbon atoms, halogen, trifluoromethyl, $-CO_2R_{11}$, aryl of 6-20 carbon atoms, arylalkyl of 7-26 carbon atoms, or a saturated, unsaturated, or partially unsaturated heterocyclic ring or ring system of 4-14 atoms, containing 1-4 heteroatoms selected from N, O, and S

wherein the nitrogen or sulfur atoms are optionally oxidized and nitrogen is optionally quaternized;

R_{10} is hydrogen, $-COR_{11}$, $-CONHR_{11}$, $-P(=O)(OH)OR_{11}$, or $-CO(CH_2)_nCH(NHR_{12})CO_2R_{11}$;

R_{11} is hydrogen, alkyl of 1-6 carbon atoms, aryl of 6-20 carbon atoms, or arylalkyl of 7-26 carbon atoms;

R_{12} is hydrogen or $-CO_2R_{11}$;

n = 0-3,

or a pharmaceutically acceptable salt thereof.

10. (Original) A method of treating or inhibiting psoriasis in a mammal in need thereof, which comprises administering to said mammal an effective amount of a compound of formulae I or II having the structure



I



II

wherein

R_1 is hydrogen, alkyl of 1-6 carbon atoms, alkenyl of 2-7 carbon atoms, cycloalkyi of 3-8 carbon atoms, cycloalkenyl of 4-8 carbon atoms, aryl of 6-20 carbon atoms, arylalkyl of 7-26 carbon atoms, or a saturated, unsaturated, or partially unsaturated heterocyclic

ring or ring system of 4-14 atoms, containing 1-4 heteroatoms selected from N, O, and S;

R_2, R_3, R_4, and R_5, are each, independently, hydrogen, alkyl of 1-6 carbon atoms, alkenyl of 2-7 carbon atoms, hydroxy, alkoxy of 1-6 carbon atoms, aryloxy of 6-20 carbon atoms, halogen, trifluoromethyl, -CN, $-NO_2$, -CHO, or $-CO_2R_{11}$;

R_6, R_7, R_8, and R_9, are each, independently, hydrogen, alkyl of 1-6 carbon atoms, alkenyl of 2-7 carbon atoms, hydroxy, alkoxy of 1-6 carbon atoms, aryloxy of 6-20 carbon atoms, halogen, trifluoromethyl, $-CO_2R_{11}$, aryl of 6-20 carbon atoms, arylalkyi of 7-26 carbon atoms, or a saturated, unsaturated, or partially unsaturated heterocyclic ring or ring system of 4-14 atoms, containing 1-4 heteroatoms selected from N, O, and S wherein the nitrogen or sulfur atoms are optionally oxidized and nitrogen is optionally quaternized;

R_{10} is hydrogen, $-COR_{11}$, $-CONHR_{11}$, $-P(=O)(OH)OR_{11}$, or $-CO(CH_2)_nCH(NHR_12)CO_2R_{11}$;

R_{11} is hydrogen, alkyl of 1-6 carbon atoms, aryl of 6-20 carbon atoms, or arylalkyi of 7-26 carbon atoms;

R_{12} is hydrogen or $-CO_2R_{11}$;

n = 0-3,

or a pharmaceutically acceptable salt thereof.

11. (Original) A method of treating or inhibiting asthma or chronic obstructive pulmonary disease in a mammal in need thereof, which comprises administering to said mammal an effective amount of a compound of formulae I or II having the structure



I



II

wherein

R_2 is hydrogen, alkyl of 1-6 carbon atoms, alkenyl of 2-7 carbon atoms, cycloalkyl of 3-8 carbon atoms, cycloalkenyl of 4-8 carbon atoms, aryl of 6-20 carbon atoms, arylalkyl of 7-26 carbon atoms, or a saturated, unsaturated, or partially unsaturated heterocyclic ring or ring system of 4-14 atoms, containing 1-4 heteroatoms selected from N, O, and S;

R_2, R_3, R_4, and R_5, are each, independently, hydrogen, alkyl of 1-6 carbon atoms, alkenyl of 2-7 carbon atoms, hydroxy, alkoxy of 1-6 carbon atoms, aryloxy of 6-20 carbon atoms, halogen, trifluoromethyl, -CN, $-NO_2$, -CHO, or $-CO_2R_{11}$;

R_6, R_7, R_8, and R_9, are each, independently, hydrogen, alkyl of 1-6 carbon atoms, alkenyl of 2-7 carbon atoms, hydroxy, alkoxy of 1-6 carbon atoms, aryloxy of 6-20 carbon atoms, halogen, trifluoromethyl, $-CO_2R_{11}$, aryl of 6-20 carbon atoms, arylalkyl of 7-26 carbon atoms, or a saturated, unsaturated, or partially unsaturated heterocyclic ring or ring system of 4-14 atoms, containing 1-4 heteroatoms selected from N, O, and S wherein the nitrogen or sulfur atoms are optionally oxidized and nitrogen is optionally quaternized;

R_{10} is hydrogen, $-COR_{11}$, $-CONHR_{11}$, $-P(=O)(OH)OR_{11}$, or $-CO(CH_2)_nCH(NHR_{12})CO_2R_{11}$;

R_{11} is hydrogen, alkyl of 1-6 carbon atoms, aryl of 6-20 carbon atoms, or arylalkyl of 7-26 carbon atoms;

R_{12} is hydrogen or $-CO_2R_{11}$;

n = 0-3,

or a pharmaceutically acceptable salt thereof.

12. (Original) A method of treating or inhibiting stroke, ischemia, or reperfusion injury in a mammal in need thereof, which comprises administering to said mammal an effective amount of a compound of formulae I or II having the structure



I



II

wherein

R_1 is hydrogen, alkyl of 1-6 carbon atoms, alkenyl of 2-7 carbon atoms, cycloalkyi of 3-8 carbon atoms, cycloalkenyl of 4-8 carbon atoms, aryl of 6-20 carbon atoms, arylalkyl of 7-26 carbon atoms, or a saturated, unsaturated, or partially unsaturated heterocyclic ring or ring system of 4-14 atoms, containing 1-4 heteroatoms selected from N, O, and S;

R_2, R_3, R_4, and R_5, are each, independently, hydrogen, alkyl of 1-6 carbon atoms, alkenyl of 2-7 carbon atoms, hydroxy, alkoxy of 1-6 carbon atoms, aryloxy of 6-20 carbon atoms, halogen, trifluoromethyl, -CN, $-NO_2$, -CHO, or-CO_2R_{11};

R_6, R_7, R_8, and R_9, are each, independently, hydrogen, alkyl of 1-6 carbon atoms, alkenyl of 2-7 carbon atoms, hydroxy, alkoxy of 1-6 carbon atoms, aryloxy of 6-20 carbon atoms, halogen, trifluoromethyl, $-CO_2R_{11}$, aryl of 6-20 carbon atoms, arylalkyl of 7-26 carbon atoms, or a saturated, unsaturated, or partially unsaturated heterocyclic ring or

ring system of 4-14 atoms, containing 1-4 heteroatoms selected from N, O, and S wherein the nitrogen or sulfur atoms are optionally oxidized and nitrogen is optionally quaternized;

R_{10} is hydrogen, $-COR_{11}$, $-CONHR_{11}$, $-P(=O)(OH)OR_{11}$, or $-CO(CH_2)_nCH(NHR_{12})CO_2R_{11}$;

R_{11} is hydrogen, alkyl of 1-6 carbon atoms, aryl of 6-20 carbon atoms, or arylalkyl of 7-26 carbon atoms;

R_{12} is hydrogen or $-CO_2 R_{11}$;

n = 0-3,

or a pharmaceutically acceptable salt thereof.

13. (Original) A method of lowering cholesterol, triglycerides, Lp(a), and LDL levels; inhibiting or treating hypercholesteremia, hyperlipidemia, cardiovascular disease, atherosclerosis, acute coronary syndrome, peripheral vascular disease, restenosis, or vasospasm in a mammal in need thereof, which comprises administering to said mammal an effective amount of a compound of formulae I or II having the structure



I



II

wherein

R_1 is hydrogen, alkyl of 1-6 carbon atoms, alkenyl of 2-7 carbon atoms, cycloalkyi of 3-8 carbon atoms, cycloalkenyl of 4-8 carbon atoms, aryl of 6-20 carbon atoms, arylalkyl of 7-26 carbon atoms, or a saturated, unsaturated, or partially unsaturated heterocyclic ring or ring system of 4-14 atoms, containing 1-4 heteroatoms selected from N, O, and S;

R_2, R_3, R_4, and R_5, are each, independently, hydrogen, alkyl of 1-6 carbon atoms, alkenyl of 2-7 carbon atoms, hydroxy, alkoxy of 1-6 carbon atoms, aryloxy of 6-20 carbon atoms, halogen, trifluoromethyl, -CN, $-NO_2$, -CHO, or-CO_2R_{11};

R_6, R_7, R_8, and R_9, are each, independently, hydrogen, alkyl of 1-6 carbon atoms, alkenyl of 2-7 carbon atoms, hydroxy, alkoxy of 1-6 carbon atoms, aryloxy of 6-20 carbon atoms, halogen, trifluoromethyl, $-CO_2R_{11}$, aryl of 6-20 carbon atoms, arylalkyl of 7-26 carbon atoms, or a saturated, unsaturated, or partially unsaturated heterocyclic ring or ring system of 4-14 atoms, containing 1-4 heteroatoms selected from N, O, and S wherein the nitrogen or sulfur atoms are optionally oxidized and nitrogen is optionally quaternized;

R_{10} is hydrogen, $-COR_{11}$, $-CONHR_{11}$, -P(=O)(OH)O R_{11}, or $-CO(CH_2)_nCH(NHR_{12})CO_2R_{11}$;

R_{11} is hydrogen, alkyl of 1-6 carbon atoms, aryl of 6-20 carbon atoms, or arylalkyl of 7-26 carbon atoms;

R_{12} is hydrogen or $-CO_2R_{11}$;

n = 0-3,

or a pharmaceutically acceptable salt thereof.

14. (Original) A method of treating or inhibiting Alzheimer's disease, cognitive decline, or senile dementia in a mammal in need thereof, which comprises administering to said mammal an effective amount of a compound of formulae I or II having the structure



I



II

wherein

R_1 is hydrogen, alkyl of 1-6 carbon atoms, alkenyl of 2-7 carbon atoms, cycloalkyi of 3-8 carbon atoms, cycloalkenyl of 4-8 carbon atoms, aryl of 6-20 carbon atoms, arylalkyl of 7-26 carbon atoms, or a saturated, unsaturated, or partially unsaturated heterocyclic ring or ring system of 4-14 atoms, containing 1-4 heteroatoms selected from N, O, and S;

R_2, R_3, R_4, and R_5, are each, independently, hydrogen, alkyl of 1-6 carbon atoms, alkenyl of 2-7 carbon atoms, hydroxy, alkoxy of 1-6 carbon atoms, aryloxy of 6-20 carbon atoms, halogen, trifluoromethyl, -CN, $-NO_2$, -CHO, or $-CO_2R_{11}$;

R_6, R_7, R_8, and R_9, are each, independently, hydrogen, alkyl of 1-6 carbon atoms, alkenyl of 2-7 carbon atoms, hydroxy, alkoxy of 1-6 carbon atoms, aryloxy of 6-20 carbon atoms, halogen, trifluoromethyl, $-CO_2R_{11}$, aryl of 6-20 carbon atoms, arylalkyl of 7-26 carbon atoms, or a saturated, unsaturated, or partially unsaturated heterocyclic ring or ring system of 4-14 atoms, containing 1-4 heteroatoms selected from N, O, and S wherein the nitrogen or sulfur atoms are optionally oxidized and nitrogen is optionally quaternized;

R_{10} is hydrogen, $-COR_{11}$, $-CONHR_{11}$, $-P(=O)(OH)OR_{11}$, or $-CO(CH_2)_nCH(NHR_{12})CO_2R_{11}$;

R_{11} is hydrogen, alkyl of 1-6 carbon atoms, aryl of 6-20 carbon atoms, or arylalkyi of 7-26 carbon atoms; R_{12} is hydrogen or $-CO_2Rn$;

n = 0-3,

or a pharmaceutically acceptable salt thereof.

15. (Original) A method of treating or inhibiting type II diabetes in a mammal in need thereof, which comprises administering to said mammal an effective amount of a compound of formulae I or II having the structure



I



II

wherein

R_1 is hydrogen, alkyl of 1-6 carbon atoms, alkenyl of 2-7 carbon atoms, cycloalkyl of 3-8 carbon atoms, cycloalkenyl of 4-8 carbon atoms, aryl of 6-20 carbon atoms, arylalkyi of 7-26 carbon atoms, or a saturated, unsaturated, or partially unsaturated heterocyclic ring or ring system of 4-14 atoms, containing 1-4 heteroatoms selected from N, O, and S;

R_2, R_3, R_4, and R_5, are each, independently, hydrogen, alkyl of 1-6 carbon atoms, alkenyl of 2-7 carbon atoms, hydroxy, alkoxy of 1-6 carbon atoms, aryloxy of 6-20 carbon atoms, halogen, trifluoromethyl, -CN, $-NO_2$, -CHO, or $-CO_2R_{11}$,

R_6, R_7, R_8, and R_9, are each, independently, hydrogen, alkyl of 1-6 carbon atoms, alkenyl of 2-7 carbon atoms, hydroxy, alkoxy of 1-6 carbon atoms, aryloxy of 6-20 carbon atoms, halogen, trifluoromethyl, $-CO_2R_{11}$, aryl of 6-20 carbon atoms, arylalkyl of 7-26 carbon atoms, or a saturated, unsaturated, or partially unsaturated heterocyclic ring or ring system of 4-14 atoms, containing 1-4 heteroatoms selected from N, O, and S wherein the nitrogen or sulfur atoms are optionally oxidized and nitrogen is optionally quaternized;

R_{10} is hydrogen, $-COR_{11}$, $-CONHR_{11}$, $-P(=O)(OH)OR_{11}$, or $-CO(CH_2)_nCH(NHR_{12})CO_2\ R_{11}$;

R_{11} is hydrogen, alkyl of 1-6 carbon atoms, aryl of 6-20 carbon atoms, or arylalkyl of 7-26 carbon atoms;

R_{12} is hydrogen or $-CO_2R_{11}$;

n = 0-3,

or a pharmaceutically acceptable salt thereof.

16. (Original) A method of treating or inhibiting sepsis in a mammal in need thereof, which comprises administering to said mammal an effective amount of a compound of formulae I or II having the structure



I



II

wherein

R_1 is hydrogen, alkyl of 1-6 carbon atoms, alkenyl of 2-7 carbon atoms, cycloalkyi of 3-8 carbon atoms, cycloalkenyl of 4-8 carbon atoms, aryl of 6-20 carbon atoms, arylalkyl of 7-26 carbon atoms, or a saturated, unsaturated, or partially unsaturated heterocyclic ring or ring system of 4-14 atoms, containing 1-4 heteroatoms selected from N, O, and S;

R_2, R_3, R_4, and R_5, are each, independently, hydrogen, alkyl of 1-6 carbon atoms, alkenyl of 2-7 carbon atoms, hydroxy, alkoxy of 1-6 carbon atoms, aryloxy of 6-20 carbon atoms, halogen, trifluoromethyl, -CN, $-NO_2$, -CHO, or-CO_2R_{11};

R_6, R_7, R_8, and R_9, are each, independently, hydrogen, alkyl of 1-6 carbon atoms, alkenyl of 2-7 carbon atoms, hydroxy, alkoxy of 1-6 carbon atoms, aryloxy of 6-20 carbon atoms, halogen, trifluoromethyl, -CO_2Ri-j, aryl of 6-20 carbon atoms, arylalkyl of 7-26 carbon atoms, or a saturated, unsaturated, or partially unsaturated heterocyclic ring or ring system of 4-14 atoms, containing 1-4 heteroatoms selected from N, O, and S wherein the nitrogen or sulfur atoms are optionally oxidized and nitrogen is optionally quaternized;

R_{10} is hydrogen, -COR_{11}; -$CONHR_{11}$, -P(=O)(OH)OR_{11}, or -$CO(CH_2)_nCH(NHR_{12})CO_2R_{11}$;

R_{11} is hydrogen, alkyl of 1-6 carbon atoms, aryl of 6-20 carbon atoms, or arylalkyl of 7-26 carbon atoms;

R_{12} is hydrogen or -CO_2R_{11};

n = 0-3,

or a pharmaceutically acceptable salt thereof.